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Acute kidney injury (AKI) activates pathways of cell death and
cell proliferation. Although seemingly discrete and unrelated
mechanisms, these pathways can now be shown to be
connected and even to be controlled by similar pathways.
The dependence of the severity of renal-cell injury on cell
cycle pathways can be used to control and perhaps to
prevent acute kidney injury. This review is written to address
the correlation between cellular life and death in kidney
tubules, especially in acute kidney injury.
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In a recent study of adult hospital admissions, increases in
serum creatinine (0.5mg per 100ml) were reported in more
than 14% of adult admissions, and were associated with a
6.5-fold increased mortality.1 Despite our increased under-
standing of the incidence and consequences of acute kidney
injury (AKI), morbidity and mortality associated with this
syndrome in critically ill patients have remained above 50%.2
AKI is a heterogeneous syndrome, and the possible contri-
buting causes are similarly heterogeneous, ranging from
inflammation and inflammatory cytokines3–11 to members of
cell death pathways12–15 and mitogen-activated protein
kinases.16 There is agreement that the cell death that
accompanies AKI contributes significantly to the severity of
the syndrome. In addition, we have shown that both
apoptotic cell death in vitro and necrotic tubular cell death
in vivo are associated with cisplatin cytotoxicity and are
dependent on the activation of certain enzymes of the cell
cycle (see below). It is therefore appropriate to discuss
possible correlations between these two pathways.
KIDNEY CELL DEATH
In multicellular organisms, it is fairly obvious that without
life there can be no death. However, this is less obvious on a
cellular level. Several types of cell death have been
characterized in eukaryotes, primarily by morphological
criteria. For tubular cell death in AKI and for cultured
kidney cells, the processes of necrosis and apoptosis are most
apparent (Figure 1). The morphological differences between
these two types of cell death were first described in 1972,17
and the pathways culminating in these different morpho-
logies are active avenues of investigation.18 In the in vitro
model of AKI, the form of death observed in kidney cell
cultures after cisplatin administration is initially apoptosis,
but eventually these cells seem to be necrotic, a morphology
characterized as ‘secondary necrosis.’ In rodent models of
AKI, both necrotic and apoptotic cells are found, with
necrosis primarily found in the S3 segment of proximal
tubules, whereas apoptosis occurs in distal tubules. The
overall contribution of these two morphologically distinct
forms of cell death to that observed in tubules is difficult to
determine. First, apoptotic cells in vivo are rapidly engulfed
by neighboring cells, whereas necrotic cells are usually not
removed efficiently, making direct comparison inaccurate;
second, as is found in vitro, apoptotic cells can progress into
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‘secondary necrotic’ cells, with death arising from apoptosis,
but morphologically similar to necrosis. A significant in vivo
distinction between these two morphologies is that necrotic
cells lyse, resulting in inflammation, whereas apoptotic cells
can be removed before lysis. Inflammation is a major
complication of AKI, and Reeves et al.19 found that tumor
necrosis factor, a primary contributor to nephrotoxicity, is
produced by kidney cells in vivo after cisplatin injection. At
the same time, however, experimental evidences linking the
apoptotic and necrotic forms of cell death are emerging. It is
known that apoptosis is an active process, requiring energy
and following distinct metabolic pathways, but similarly,
necrotic cell death may also be regulated by a set of signal
transduction pathways and catabolic mechanisms and is as
well controlled and programmed as apoptosis.20,21 Of
particular relevance in kidney cell death, using cultured
mouse proximal tubular cells, Lieberthal et al.22 showed that
cell death characterized either as primarily apoptosis or as
primarily necrosis could be induced by the same agent
(cisplatin), showing a possible interrelationship between
these two processes. Similarly, activation of a cell-cycle
enzyme-dependent pathway common to both cell death
pathways can be inferred by our results showing that
cyclin-dependent kinase 2 (Cdk2) inhibition can protect
both cisplatin-induced apoptosis in vitro and necrosis in vivo
(see below). Two other major forms of cell death, that is
cornification and autophagy, have been defined by the
Nomenclature Committee on Cell Death,23 although it is
not certain how much these two forms of cell death
contribute to AKI. Specifically, cornification occurs exclu-
sively in the epidermis, whereas autophagy has a clear role in
pro-survival pathways, but its role in cell death is less clear,24
and in AKI, autophagy was reported to be cytoprotective.25
Many of the molecular pathways leading to apoptotic cell
death have been extensively studied and elaborated, whereas
those leading to cell death by necrosis are not yet as clear.
This discussion, therefore, will focus on several aspects of the
apoptotic pathways, keeping in mind that these molecular
events could be shared by other forms of cell death. A more
detailed discussion of apoptosis focused on cisplatin-induced
AKI has recently been published.26 Cellular death by
apoptosis (Figure 2) proceeds in an orderly fashion and is
an active process requiring specific proteins. Apoptotic
pathways were first described in the nematode Caenorhabditis
elegans27 in which the role of proteases (now called caspases)
in cell death was shown. Structurally similar enzymes were
soon isolated from human and murine cells.28 Caspases are
Figure 1 |Kidney cell death in vivo and in vitro.
Photomicrograph sections of periodic acid-schiff–stained mouse
kidney (a and b) showing the corticomedullary junction on the
left and the cortex region on the right of each micrograph.
Photomicrograph of cultured mouse kidney cells (TKPTS) with
Nomarski imaging (c and d) or fixed cells stained with
40,60-diamidino-2-phenylindole (DAPI) (e and f). Tissues and cells
were from untreated mice and cultures (a, c, and e), from mice
3 days after 20mg/kg cisplatin injection (b), or from cultures 1 day
after the addition of 25 mM cisplatin.
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Figure 2 | Simplified version of apoptotic cell death pathways.
Extrinsic, receptor-mediated pathway illustrated on the left and
intrinsic pathway illustrated on the right. Both pathways depicted
converge on the activation of caspase-3, but other caspase-
independent pathways also exist.
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members of a family of approximately 13 cysteine proteases
that fall into two groups, ‘initiator’ and ‘executioner’
caspases. Caspase activation is generally considered to be a
‘point of no return’ in cell death pathways, and even
prevention of caspase activity usually just results in diversion
into cell death pathways that are independent of these
proteases.29–31 However, recently, metabolic roles for active
caspases that do not result in cell death have been observed,32
so that caspase activation per se does not determine cell
death, and its proapoptotic activity is likely to be dependent
on other cellular events. The cascades of cell death are
initiated by primarily two origins, either an intrinsic pathway
that can start from cytoplasmic events such as endoplasmic
reticulum damage and nuclear events such as DNA damage,
or an extrinsic pathway that communicates through cell
surface death receptors such as the tumor necrosis factor
receptor. After initiation, many of the death pathways require
disruption of the outer membrane of mitochondria and
release of mitochondrial proteins, such as cytochrome c.33
These internal mitochondrial proteins are usually important
for various mitochondrial functions, but after release into the
cytoplasm, they can activate caspases and DNases. The
interaction of the death pathways with the mitochondrial
membrane often is mediated by a family of proteins that can
either facilitate or interrupt the pathway. Proapoptotic family
members, such as Bax and Bak, are believed to form pores in
the outer mitochondrial membrane thereby causing release,
but antiapoptotic family members, such as Bcl-2 and Bcl-xL,
antagonize pore formation.34 Depending on the combination
of family members participating in the response, mitochon-
drial membrane damage can be either alleviated or worsened.
One of the still unanswered questions is the mechanism by
which a signal initiated by cellular stress is communicated to
pro- and antiapoptotic proteins to control the mitochondrial
pore. After cytochrome c enters the cytoplasm, it induces a
conformational change in Apaf-1 and, together with procas-
pase-9, forms a heptameric structure (the ‘apoptosome’),35
activating the initiator protease, caspase-9. Downstream targets
of caspase-9 are executioner proteases, caspase-3 and -7. Other
pro-apoptotic factors can also be liberated from the mitochon-
dria after outer membrane permeabilization. These proteins
include AIF (apoptosis-inducing factor36) and endonuclease
G,37 which translocate to the nucleus to participate in cell death
that can be independent of caspase activation.
Although most of the proteins, including proteases,
DNases, and activators of pro-death molecules, were first
described because of their apoptotic function, almost all are
now known to have vital functions unrelated to cell death
pathways.38 The roles of ‘death’ proteins in cellular life, and
the role of a metabolic protein, cytochrome c, in death
pathways, illustrate the conservation in evolution resulting in
seemingly unrelated and possibly conflicting functions for
proteins. We now provide substantial evidence that a protein
originally identified as necessary for cell division, Cdk2, is
required for pathways of both apoptosis and necrosis in the
kidney.
CELL CYCLE EVENTS
When we talk about cell death in relation to the kidney, its
importance is obvious, especially in the setting of AKI. But
less than 1% of kidney tubular cells are proliferating, and this
small percentage declines even further with age.39 Several
years ago, it was noted that in response to injury, many
normally quiescent kidney cells enter the cell cycle (Figure 3).
This process begins shortly after injury, in which both
necrotic cells and replicating cells line the injured proximal
tubules. There are increases in nuclear proliferating cell
nuclear antigen (PCNA),40–42 incorporation of 3H-thymidine
and 5-bromo-2-deoxyuridine into nuclear DNA, and induc-
tion of mRNA for ‘immediate-early’ genes, for example c-fos,
c-jun, and egr-1,43,44 whose expression is frequently asso-
ciated with the entry of cells from quiescence into the cell
cycle. It is clear that damage of cells that results in cell death
also results in cell proliferation. It is reasonable to assume
that these events occur because of cell stress and/or cell death,
but it is not certain the extent to which they contribute to
injury or to protection and recovery.
Cell division is a carefully synchronized sequence of events
in which genomic DNA is replicated, usually followed by
equal separation of the genome into two similar cells. The cell
division cycle was initially divided into two phases: mitotic
phase and interphase, which is the period between mitoses.
Figure 3 |Cell-cycle analysis of kidney after cisplatin injection.
(a) Immunodetection of nuclear BrdU incorporation 4 days
after injection and (b) that of nuclear PCNA localization 1 day
after injection. Sections were from p21(/) mice. BrdU,
5-bromo-2-deoxyuridine.
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In 1953, James Watson and Francis Crick elegantly described
their model for DNA structure and suggested a mechanism
for replication by noting that ‘it has not escaped our notice
that the specific pairing we have postulated immediately
suggests a possible copying mechanism for the genetic
material.’45 At about the same time, Howard and Pelc,46
working with Vicia faba root tips, found that radioactive
phosphorus was incorporated into DNA only during a
distinct segment of the interphase, which was separated in
time from the beginning to the end of mitosis. This
observation ultimately led to the division of the cell cycle
into four phases: the mitotic phase M, the DNA synthetic
phase S, and the pre- and post-DNA synthetic phases, G1 and
G2, respectively.
An important aspect of the cycle is the necessity for it to
proceed only in one direction, ensuring that only one DNA
synthetic phase occurs for each mitotic phase. The first set of
controls for this system was discovered by Tim Hunt and
Tom Evans47 at the 1982 Physiology course at Woods Hole.
They reported a protein, later identified as cyclin B, that was
continuously synthesized after fertilization of sea urchin eggs
and then almost completely degraded about 10min before
the eggs divided. Characterization of other ‘cyclic’ proteins
steadily accumulated. These observations established that
some cell cycle regulatory proteins are periodically synthe-
sized and degraded during the cycle, which helps maintain
unidirectional progression. It was shown that cyclin D is
synthesized in early G1 and degraded as cells exit G1 and enter
S phase. Cyclin E is synthesized in late G1 and is degraded in
S, and cyclin A is synthesized in S and is degraded as cells
progress through S and exit G2. Cyclin B is synthesized in late
G2 and degraded during late M phase, before the cells exit
mitosis. The cyclins were found to act as heterodimers in
combination with Cdk subunits, which had been found
several years previously in yeast48,49 and, by homology, in
humans.50 The Cdk subunit is a serine/threonine protein
kinase51 that is inactive unless associated with a cyclin. The
binding of the cyclin to its Cdk confers basal kinase
activity;52,53 full activity is dependent on its phosphorylation
at certain residues and its dephosphorylation at other
residues.54 In vertebrates, several different cyclins and Cdk
partners are sequentially present and active throughout the
cell cycle, with cyclin D pairing with Cdk4/6, cyclin E with
Cdk2, cyclin A with Cdk2 and then with Cdk1, and cyclin B
with Cdk1. The observations that different cyclin-Cdk pairings
caused sequential activation of different Cdks at various stages
of the cell cycle and experiments with antibody injection,
antisense and dominant-negative repression55 of these proteins
resulted in the view of the cycle that these different cyclins and
Cdks were essential for cell cycle progression. This would be a
more complex system than is observed in yeast, in which only
one Cdk is active during the cycle.
However, recent work using mouse knockout techniques
reveals a much different story, in which most of the cyclins,
with the exception of cyclin A2 and cyclin B1 (there are two
cyclin A and three cyclin B genes known), and Cdk2, -4,
and -6, with the exception of Cdk1, can be individually
knocked out without a major phenotype. For the Cdks, even
a triple knockout of Cdk2, -4, and -6 does not prevent cell
cycle progression in mouse embryo fibroblasts. Rather than
being essential for cell cycle activity, these Cdks and cyclins
were found to be important for specific cellular functions
and/or specific organogenesis. For example, cyclin E was
found important for cells to enter the cycle after quiescence,
Cdk2 was found essential for male and female fertility,
inferring a requirement during meiosis, Cdk4 for pancreatic
b cells, anterior pituitary cells, and Leydig cell development,
and Cdk6 for complete erythroid differentiation. Double
knockouts of Cdks were found to be important in different
organogeneses: Cdk4 plus Cdk6 for hematopoietic develop-
ment and Cdk2 plus Cdk4 for cardiomyocyte proliferation.
This emerging picture has prompted Hunt and co-workers56
to propose a ‘threshold’ model of cell cycle control in which
different localizations and increasing Cdk activity during the
cell cycle control progression from G1 phase through mitosis.
A similar model in fission yeast was promoted 10 years
previously by Stern and Nurse.57 Recently, Philipp Kaldis58
found that genetic substitution of Cdk1 by Cdk2 did not
restore the viability of early mouse embryos, even though
Cdk2 was expressed from the Cdk1 locus. This has shown the
importance of molecular specificity of the cyclin-Cdk
heterodimer, at least for Cdk1 and Cdk2, or alternately, in
keeping with a threshold model, that Cdk2 may not have as
high an intrinsic kinase activity as does Cdk1. Regardless of
the degree to which the Cdks and cyclins are redundant, there
is agreement that the kinase activity of the Cdks and possibly
other protein kinases either permits or prevents progression
of the cell cycle from one event to another, but for most of the
substrates, it is not clear how this control occurs. The complexity
of the process was recently revealed by Dephoure et al.,59 who
identified over 14,000 phosphorylation events involving more
than 3600 proteins for one round of the cell cycle.
In addition to the orderly progression from one cell cycle
stage to the next, several protein effectors respond to DNA
damage, incomplete DNA synthesis, and successful comple-
tion of mitosis. The idea of ‘checkpoints’ throughout the cell
cycle was initially proposed by Hartwell and Weinert,60 after
their finding that some yeast mutants failed to arrest the cell
cycle in response to radiation. A similar DNA damage
checkpoint was found in human cells involving the
accumulation of the p53 protein61 in response to damaged
DNA in which cells were prevented from cell cycle
progression. These checkpoint effectors, which also go under
the name of cyclin-dependent kinase inhibitors, primarily
control the entry of cells into S and M phases both by
inhibiting and by stimulating Cdk activity. In humans and
other vertebrates, there are two families of these proteins. The
first protein characterized from these families was p21, a
21-kDa protein62 that is constitutively expressed at low levels.
The family also contains p2763–66 and p57.67,68 The p21
cDNA was cloned simultaneously by three groups, each with
a different assay for its presence, revealing the spectrum of
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activities of the p21 protein. The separate criteria were
induction by p53,69 cyclin kinase inhibition,70,71 and
induction of senescence.72 Overexpression of p21 has other
effects on cell fate, ranging from cell cycle interrup-
tion62,71,73–75 to activation,76 from terminal differentia-
tion77–82 to inhibition of regeneration83 and induction of
cellular senescence.84 The events controlled by p21 are likely
the product of the cell type and the circumstances of its
induction. In normal replicative cycles, p21 and p27 are
bound to Cdk2, repressing progression into late G1 and S. As
the abundance and the activity of the primary G1 cyclin-Cdk
(cyclin D-Cdk4/6) rises, this complex binds to p21/27,
effectively reducing the amount of p21/27 available for
binding and inhibiting cyclin-Cdk2. In late G1, active Cdk2
phosphorylates p21/27, starting the process of p21/27
ubiquitination and proteasomal degradation.85 It is remark-
able that in the combined absences of Cdk4, Cdk6, and Cdk2,
the coordination of p21/27 titration, inhibition, and
degradation can be accomplished solely by Cdk1. Perhaps
in view of these knockout results, our view of this level of
control will have to be modified.
A second family of small-molecular-weight proteins, the
‘INK4’ family (inhibitors of Cdk4), ranging from 14 to
19 kDa, bind the kinase subunit of the cyclin D heteroduplex
(Cdk4/6), and arrest the cell cycle in the G1 phase.
73,86–89
The p16INK4A-p15INK4B locus occupies a small region
(35 kb) of the human genome and is deleted in a wide
spectrum of tumors including melanoma, pancreatic adeno-
carcinoma, glioblastoma, certain leukemias, non-small-cell
lung cancer, and bladder carcinoma (reviewed in Kim and
Sharpless90). Other members of this family have not been
associated with tumor suppression and although differen-
tially expressed during development, their functions may
be redundant.
The relevance of the cell cycle and its controls is
particularly important in cultured cells and models of AKI
using these in vitro methods. However, most cells in kidney
in vivo are quiescent and enter the cell cycle only after
stimulation, such as that induced by stress. The distinction
between cycling and quiescent (and senescent) cells is actively
being investigated.91 Comparisons between quiescent and
cycling cells in vitro rely on quiescence being induced by cell
cycle inhibitors, withdrawal of growth factors, and so on.
Similarly, comparisons between in vivo and in vitro models of
AKI rely on comparing quiescent and actively dividing cells.
These comparisons can result in generalizations being
based on ‘apples versus oranges’ logic. For example, as
described above, cisplatin-induced toxicity results primarily
in apoptotic cell death in vitro but necrotic cell death in vivo.
We argue that this difference merely reflects the environment
and cell cycle characteristics of the stressed cells and not the
activation of different cell death pathways having no relevant
comparison. But regardless of the accuracy of the compar-
isons, the underlying mechanism(s) of cytotoxicity affecting
cell death will provide insights into the prevention and cure
of AKI.
CYCLIN INHIBITOR INDUCTION AND ITS INFLUENCE IN AKI
When cells of the injured kidney enter the cell cycle, there is a
rapid induction of p21, but not other family members, in
several models of AKI (Figure 4a), such as cisplatin exposure,
ischemia–reperfusion, and ureteral obstruction.92 The p21
protein was localized to both distal and proximal tubule cells
by immunohistochemistry. We studied the effect(s) of p21
induction in AKI by comparing wild-type p21(þ /þ ) mice
with mice homozygous for a p21 gene deletion. 5-bromo-2-
deoxyuridine incorporation into nuclear DNA and increases
of PCNA content were much higher after AKI in kidney cells
of p21(/) mice, compared with p21(þ /þ ) mice. The
picture that emerged was that stressing the kidney caused
cells to enter the cell cycle, whereas at the same time, the
stress induced a protein identified as a cell cycle inhibitor. But
another role of p21 was also apparent: p21 induction
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Figure 4 | Expression and consequences of p21 expression
in vivo after AKI. Northern blot analysis of p21 mRNA transcripts
in rat kidney cells (a). Control, untreated kidney. Ischemia, kidney
collected from rats after renal ischemia, in which rats were made
ischemic for 50min and killed after reflow of 0 and 30min, 1, 2, 4,
24, and 48 h. Obstruction, kidney obtained from rats after 24 h
unilateral and or bilateral ureteral obstruction. Cisplatin, kidney
obtained from rats after treatment with 7.5mg/kg cisplatin for
6, 12, 24, and 72 h. All lanes had the same amount of mRNA, as
assessed by hybridization to probe specific for constitutively
expressed glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA (not shown). Immunochemical localization of p21 protein
in kidney after 50min of renal ischemia. Sections represent kidney
from untreated mice (b) and from mice 2 days after ischemia (c).
Urea nitrogen levels (d) in serum (blood urea nitrogen (BUN)) after
cisplatin administration. Values, in mg per 100ml, at each time
point represent means (±s.e.) of at least six mice. Statistically
significant differences (Po0.05) are indicated. Kaplan–Meier
survival curve comparing the survival of p21(þ /þ ) and p21(/)
mice after 50min of renal ischemia (e). AKI, acute kidney injury.
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ameliorated AKI.40,41 Following either cisplatin administration
or ischemia–reperfusion, compared with their p21(þ /þ )
littermates, p21(/) mice developed more severe morpho-
logical damage (Figure 4b,c), displayed a more rapid onset of
the physiological signs of AKI (Figure 4d), and had a higher
mortality (Figure 4e). Miyaji et al.93 speculated that p21
induction could contribute to acquired resistance from
cisplatin-induced AKI. Similarly, Nath and co-workers94 found
that LLC-PK1 kidney cells were resistant to several apoptotic
stimuli by heme oxygenase-1 overexpression. They proposed
that this resistance is conferred by p21 upregulation. These
studies were recently extended by Nath et al.95 using a rat
proximal tubule cell culture in which blocking the apoptotic
effects of hemin was correlated with p21 induction.
Microarray analysis of mRNA before and up to 3 days
after cisplatin administration revealed that p21 is the most
highly upregulated gene after exposure (Price, PM et al.,
unpublished results). As p21 is induced to such high levels
after AKI, it was not apparent whether expression before AKI
would protect any more than the endogenous gene activa-
tion. However, using cultured kidney proximal tubule cells
and adenoviral transduction, we expressed p21 before
cisplatin was administered and found that it protected from
apoptosis96 (Figure 5a-c). This type of induction is
technically difficult in vivo, so we approached the problem
of the in vivo model by first determining the mechanism of
this protection. p21 binds to many proteins, but its simple
structure is conducive to fragmentation, and we showed that
only the Cdk2-binding moiety of p21 was protective97
(Figure 5d-h). This Cdk2 dependence was further shown by
Cdk2 inhibitory drugs and by dominant-negative Cdk2
transduction. One of the drugs, purvalanol, was used in vivo,
and it also protected from cisplatin nephrotoxicity.98 For the
final proof that cisplatin cytotoxicity and nephrotoxicity was
dependent on Cdk2, we relied on transgenics that expressed
either p21 or dominant-negative Cdk2 under the control of a
proximal tubule-specific testosterone-inducible promoter,
which was obtained from Curt Sigmund. Induction of either
transgene protected from cisplatin nephrotoxicity (Figure 6).
These findings showed an unexpected relationship between
cell cycle, that is cell ‘life’ and cell death pathways: pathways
of cell death are dependent on a cell cycle protein. These
findings also highlight a similarity between the cell death
pathways of apoptosis and necrosis. As both cisplatin-
induced necrosis and apoptosis were dependent on Cdk2,
at the least this enzyme activity is in common, even though
the substrate(s) in these death pathways can be different and
remains to be determined.
The use of cell cycle inhibitors to ameliorate AKI, in which
cell cycle activity should be beneficial to replace damaged
cells to restore lost function, seems to be counter-intuitive. In
fact, growth factors such as erythropoietin, hepatocyte
growth factor, and insulin-like growth factor-1 have been
used to lessen injury and/or accelerate recovery from AKI in
rodents (cited in Jo et al.99). The mechanism of the protective
effect by these agents has not been determined, but could
be a combination of increased proliferation of resident or
bone marrow endothelial progenitor cells, or reduced
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Figure 5 | Fluorescence-activated cell sorter (FACS) analysis and light microscopy of TKPTS cells of the effect of different domains of
p21 on the protection of cisplatin-induced cell death. Analyses were performed to quantify cell death of TKPTS cells without or with
25mM cisplatin in the absence or presence of adenovirus encoding p21 full-length or truncations as green fluorescent protein (GFP) fusion
protein. For FACS analysis, TKPTS cells were harvested by trypsinization and collected by centrifugation. Cells were fixed and treated with
RNase A and propidium iodide and analyzed using FACSCalibur. For each culture condition, 105 cells were analyzed. The parts of the
FACS analyses representing different phases of the cell cycle are indicated. Cells in the phase of sub-G1/G0 are classified as the apoptotic
fraction. TKPTS cells were photographed using Hoffman optics before harvesting. (a) Untreated cells. (b) Cells treated for 24 h with cisplatin.
(c) Cells treated with full-length p21 adenovirus for 24 h and then for 24 h with cisplatin. (d) Cells treated with amino-terminal p21
adenovirus for 24 h and then for 24 h with cisplatin. (e) Cells treated with carboxy-terminal p21 adenovirus for 24 h and then for 24 h with
cisplatin. (f) Cells treated with p21 amino acids 1–45 adenovirus for 24 h and then for 24 h with cisplatin. (g) Cells treated with p21 amino
acids 38–91 adenovirus for 24 h and then for 24 h with cisplatin. (h) Representation of various p21 constructions with different protein-
interacting domains. Adenovirus encoding full-length, amino-terminal, carboxy-terminal, amino acids 1–45, and amino acids 38–91 of p21 as
green fluorescent protein (GFP) fusion proteins with or without different functional domains is shown. cdk2: cdk2-binding domain;
PCNA: PCNA-binding domain; procasp-3: procaspase-3-binding domain; NLS: nuclear localization sequence.
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inflammatory response to tissue damage. It is possible that a
combination of treatments, in which Cdk2 inhibition can be
used to lessen cell death, and growth factor used to stimulate
recovery, will eventually be most effective in AKI.
OTHER POSSIBLE CONNECTIONS OF CDK/CELL CYCLE
ACTIVITY AND RENAL DISEASES
A recent review focused on the use of Cdk inhibitors to treat
renal diseases.100 It is not surprising that most of these
diseases are associated with kidney cell proliferation, and it is
encouraging that these inhibitors show promise in a wide
variety of kidney-specific syndromes. The first instance of the
use of a Cdk inhibitor to treat a renal disease was in 1997,
for the treatment of mesangial proliferative glomerulo-
nephritis.101 This pioneering investigation soon was ex-
panded to include antiproliferative actions on podocytes in
experimental crescentic glomerulonephritis102 and collapsing
glomerulopathy.103 The targeting of podocytes infected with
human immunodeficiency virus-1 using Cdk inhibition was
also effective to promote podocyte differentiation and limit
proliferation.104–106 Recently, Cdk inhibition was found
useful to treat murine polycystic kidney disease,107 although
the long-term use of the particular drug used (roscovitine)
was shown to have deleterious side effects in a phase 2 trial in
IgA nephropathy.108
The finding that p21 but not other cyclin kinase family
members are induced in cortical tubules after AKI is most
likely a recapitulation of developmental expression. We
reported that in a 12.5-day mouse embryo kidney, p21
expression is highest in comma- and S-shaped bodies, and
even at E18.5, the expression is still high in S-shaped bodies
of the outer cortex; there was little if any expression in the
medulla or glomeruli.109 This is in marked contrast to the
developmental expression of p27, which was primarily
localized to the visceral epithelial cells of differentiating
glomeruli in human fetal kidney.110 As inhibitors of Cdk2,
both proteins should be equally cytoprotective after AKI,
similar to pharmacologic Cdk2 inhibitors,98 but their
beneficial effects could be altered by other functions of
these proteins.
FUTURE DIRECTIONS
As an approach to understand the mechanism of Cdk2
dependence, we are starting to identify the substrates of Cdk2
that could be related to cell death pathways. A known
substrate of Cdk2 is the retinoblastoma protein, pRb, a
repressor of E2F transcription factors. Phosphorylation of
pRb by Cdk2 dissociates it from its inhibitory interaction
with E2F, and E2F-mediated transcription is activated,
primarily during the G1–S transition of the cell cycle. A
member of the E2F family, E2F-1, which is associated with
both cell cycle stimulation and apoptosis, was upregulated
after cisplatin treatment, both in vitro and in vivo.111 A
knockout for this gene provided significant protection on
both renal function and renal morphology in mice. Although
E2F-1 is not a direct substrate of Cdk2, it is activated by Cdk2
and it affects both cell cycle and cell death pathways with
relevance in AKI. Although protection is afforded in vitro by
E2F-1 interference and in vivo by E2F-1 knockout, protection
is not as complete as by Cdk2 inhibition, suggesting that
other substrates exist.
Ultimately, a complete understanding of the interactions
of cell cycle proteins with cell death pathways will likely
begin from determinations of Cdk2 substrates. Several
recently developed methodologies,112,113 as well as mass
spectrometry,114 are natural candidates to explore this
direction. We published that Cdk2 is localized in both the
nucleus and cytoplasm in cultured kidney cells115 (Figure 7),
confirming an earlier finding of Shankland.116 Furthermore,
cisplatin-induced apoptosis in enucleated cells was
prevented by Cdk2 inhibition. We infer from this that a
Cdk2 substrate, essential to cell death pathways, is localized
in the cytoplasm.
At the same time that it becomes possible to ameliorate
AKI, it is important to keep in mind that recovery from the
injury should not be compromised, nor, as in the case of
cisplatin-induced AKI, interfering in the extrarenal function
of the drug. As was pointed out by Pabla and Dong,26
renoprotective strategies for cisplatin should not be at the
expense of the antitumor efficacy of the cisplatin therapy. In
the case of Cdk inhibitors as protectors against cisplatin-
induced AKI, the known activities of these inhibitors should
actually augment rather than reduce the effectiveness of
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Figure 6 | Effect of cdk2 inhibition either by p21 or by
dominant-negative cdk2 (DN-cdk2) expression on cisplatin-
induced AKI. The p21 and DN-cdk2 cDNA transgenes were
constructed as GFP fusion proteins and were expressed using a
testosterone-inducible kidney androgen protein (KAP2) promoter.
Relative functional damage 1, 2, and 3 days after 20mg/kg
cisplatin represented as blood urea nitrogen (BUN) (a) and
creatinine (b) in the serum. Relative morphological damage 3 days
after 20mg/kg cisplatin shown as photomicrograph sections of
periodic acid-schiff–stained mouse kidney from wild-type (c) and
testosterone-induced p21-GFP transgenic (d). The
corticomedullary junction is on the right and the cortex region is
on the left of each micrograph. AKI, acute kidney injury;
GFP, green fluorescent protein.
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chemotherapy, as at least 10 of these drugs are in clinical
trials as cancer chemotherapeutics.117–119
CONCLUSION
AKI results in cell cycle activation, which promotes injury by
Cdk2 induction and prevents injury by p21 induction. Drugs
that mimic the action of p21 to inhibit Cdk2 activity can be
used to protect from cisplatin-induced nephrotoxicity. The
actual mechanism of the relationship of Cdk2 with cell death
and whether we can interfere in this mechanism to improve
human health presents an important problem. We will
eventually understand how these cell cycle activities control
the cell death pathways and be able to use this knowledge to
prevent and treat AKI. A paraphrased comment by the
physicist Ernest Rutherford will then be appropriate: ‘All of
science is either impossible or trivial. It is impossible until
you understand it, and then it becomes trivial.’
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